Phosphorylated Extracellular Signal-regulated Kinases Are Significantly Increased in Malignant Mesothelioma

Size: px
Start display at page:

Download "Phosphorylated Extracellular Signal-regulated Kinases Are Significantly Increased in Malignant Mesothelioma"

Transcription

1 Volume 54(8): , 2006 Journal of Histochemistry & Cytochemistry ARTICLE Phosphorylated Extracellular Signal-regulated Kinases Are Significantly Increased in Malignant Mesothelioma Merivane de Melo, Margaret W. Gerbase, Joseph Curran, and Jean-Claude Pache Division of Clinical Pathology (MdM,J-CP), Department of Pulmonary Medicine (MWG), University Hospital of Geneva, Geneva, Switzerland, and Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland (JC) SUMMARY Tumorigenesis is associated with the activation of mitogenic signal transduction pathways. The expression of activated extracellular signal-regulated kinase (p-erk) may play an important role in cell proliferation of malignant mesothelioma (MM). We compare the expression of p-erk in 50 biopsy specimens of MM, non-small-cell lung cancer (NSCLC), and normal lung tissue. We hypothesized that phosphorylated extracellular signal-regulated kinase is increased in MM. We stained the sections by immunohistochemistry for activated ERK-1 and -2 and performed the quantification of the stained nuclei. Quantitative analysis of p-erk showed a high percentage score in MM ( %) as compared with NSCLC ( %) ( p,0.01) and control lung tissue ( %) ( p ). Furthermore, p-erk was found significantly higher in poorly differentiated NSCLC ( %) as compared with welldifferentiated NSCLC ( %) (p,0.01). Our data show that the nuclear quantification of p-erk is significantly increased in MM and poorly differentiated NSCLC in comparison to welldifferentiated NSCLC and normal lung tissue. These results corroborate previous experimental studies that suggest a critical role of p-erk in cell proliferation of malignant disease and may represent new targets for therapeutic agents. (J Histochem Cytochem 54: , 2006) Correspondence to: Jean-Claude Pache, MD, Division of Clinical Pathology, Centre Medical Universitaire (CMU), 1 Rue Michel- Servet, 1211 Geneva 4, Switzerland. hcuge.ch Received for publication June 14, 2005; accepted February 14, 2006 [DOI: /jhc.5A ]. KEY WORDS human malignant mesothelioma non-small-cell lung carcinoma ERK1/2 PI3K/AKT EXTRACELLULAR PROLIFERATION and differentiation factors activate cytoplasmic cascades that are composed of highly specific Ser/Thr and Tyr kinases. Some of these pathways mediate their effect via the activation of receptor tyrosine kinases such as epidermal growth factor receptor (EGF-r). The mitogen-activated protein kinases (MAPK) represent an important family of regulatory signaling molecules that serve as integration points connecting extracellular signals to the transcriptional programs of the cell. One important group of MAPKs is the extracellular signal-regulated kinases (principally ERK-1 and -2), which are activated in response to growth factors and cytokines via cell surface receptors such as EGF-r (Platanias 2003). Like many of the components of the MAPK pathways, ERKs can regulate cell proliferation both positively or negatively, depending on the cellular context in which activation takes place (Ishikawa and Kitamura 1999). Activated ERK (p-erk) translocates to the nucleus where it phosphorylates a number of transcription factors such as ELK-1, c-ets-1, and c-ets-2. This leads to the activation of genes implicated in cell proliferation such as the G1 cyclins. Numerous solid tumors are known to display constitutive levels of activated ERK-1/2, making it and other components of this MAPK signaling cascade attractive targets for anti-cancer therapy (Hilger et al. 2002; Reddy et al. 2003). In the last two decades, the worldwide incidence of human malignant pleural mesothelioma (MM) has increased dramatically (Rizzo et al. 2001). Recent epidemiological data show that, in the U.S., MM accounts for 2000 deaths per year among the reported 130,000 deaths from lung cancer (Rizzo et al. 2001; Mossman and Gruenert 2002). Epidermal growth factor and platelet-derived growth factor (PDGF) and their receptors are implicated in the process of pathogenesis in these tumors (Viallet and Sausville 1996; Cacciotti et al. 2002). Asbestos exposure causes a specific EGF-r-dependent activation of ERK-1 and -2 in rat pleural mesothelial cells (Zanella et al. 1996). The nuclear localization of phosphorylated p-erk (p-erk-1 and -2) varies among C The Histochemical Society, Inc /06/$

2 856 de Melo, Gerbase, Curran, Pache different tumors in relation to both grade and/or stage (Mandell et al. 1998; Gioeli et al. 1999; Albanell et al. 2001). Few studies have compared the morphological expression of these activated kinases in MM (Mossman et al. 1990) and non-small-cell lung carcinoma (NSCLC) (Mukohara et al. 2003; Vicent et al. 2004). However, to date no study has assessed the p-erk immunostain in MM and NSCLC. In this study we aim to analyze the expression of p-erk-1 and -2 by immunohistochemistry with a phosphospecific antibody in lung tissue sections of MM, NSCLC, and control normal lung tissue. We hypothesized that in human samples an activation of p-erk could be documented. To document the relative importance of another pathway recently described in MM (Altomare et al. 2005), we also investigated the expression of p-phosphatidylinositol 3-kinase (PI3K/AKT). A better understanding of MM and NSCLC biology could lead to new treatments of these diseases. Materials and Methods Biopsies A total of 50 specimens, diagnosed between 1996 and 2002, were analyzed in this study: 31 NSCLC (16 squamous cell carcinomas and 15 adenocarcinomas), 10 MM (6 epithelioid, 1 sarcomatous, and 3 biphasic phenotypes) and 9 non-neoplastic lung tissues. With regard to MM, asbestos exposure was known in seven of the cases, two had no history of asbestos exposure, and there were no data available for the last case. The material was fixed in buffered formalin and embedded in paraffin wax. For all the lung controls, NSCLC, and two MM, the sections came from the material of pneumectomy or pleuropneumectomy. For the eight MM, the sections came from the biopsies obtained by thoracoscopy. Histological diagnosis of lung tumors was established according to the World Health Organization criteria (Travis et al. 2004). In addition, they were graded as well differentiated or poorly differentiated. For the purpose of the present analysis, moderately differentiated tumors were included in the poorly differentiated group. All sections were stained with immunohistochemistry. p-erk stains were reviewed and diagnosed by two independent examiners. Immunohistochemistry All antibodies were purchased from Cell Signaling Laboratories Technology, Inc. (Beverly, MA). Immunostaining was performed on 4-mm tissue sections, placed on slides coated with 3- (triethoxysilyl)propylamine (Merck; Darmstadt, Germany), dewaxed in xylene, and dehydrated in alcohol. For heatinduced epitope retrieval of the p-erk stains, the specimens were washed three times in citrate buffer, ph 6.0, for 5 min in a microwave at 650W. Sections were washed with Tris-buffered saline, ph 7.6, and then rinsed in 0.1% Triton X-100/TBS for 5 min at room temperature (RT). Samples were preincubated with blocking solution (normal swine serum 10%, BSA 3% in 0.1% Triton X-100/TBS) for 30min at RT. Immunostaining was performed with two rabbit polyclonal antibodies that detect the phosphorylated forms of the MAP kinase ERK-1 and -2 (p-erk) and the total ERK protein levels (i.e., both phosphorylated and non-phosphorylated forms). After washing, the sections were incubated for 1 hr in a humid chamber at RT with the first antibody at a dilution of 1/80 for p-erk and 1/20 for ERK. After subsequent washing in 0.1% Triton X-100/TBS, samples were incubated with a biotinylated swine anti-rabbit immunoglobulin (DAKO A/S; Glostrup, Denmark) at a dilution of 1/250 for 30 min at RT. They were then rinsed in 0.1% Triton X-100/TBS before incubation in StreptAB Complex/AP (DAKO) at a 1/100 dilution for 30 min at RT. Specimens were washed and developed with Fast Red Substrate solution (DAKO) for p-erk for 15 to 30 min at RT, rinsed in H 2 O, and then counterstained with hematoxylin. They were then mounted in aqueous mounting media (Aquatex; Merck). p-akt was stained with a rabbit monoclonal antibody. The sections were treated with heat-induced epitope retrieval in a pressure cooker with a buffer citrate at ph 6.0 for 3 min. They were incubated with p-akt at a dilution 1/20 for 60 min. After subsequent washing, they were incubated with the rabbit Envision/ HRP (DAKO) and then developed with diaminobenzidine. The slides were dehydrated and mounted in Eukitt. Nonneoplastic lung tissues from nine different subjects were used as internal control. Negative controls for p-erk consisted of sections stained with an isotype-matched non-immune antibody at the same protein concentration (DAKO A/S), and normal skin was used as a positive control. Polymorphonuclear neutrophils, fibroblasts, and endothelial cells usually showed some degree of immunoreactivity and were considered as internal positive controls. Lymphocytes stained negative and were used as an internal negative control. In addition, p-erk and p-akt were preabsorbed with their respective blocking peptide. Light Microscope Analysis For p-erk immunostaining, two independent observers scored the sections by counting 6 to 10 fields (3400) with nuclear stain assessed in the non-tumoral and tumoral tissues. Stained nuclei were considered as positive independently of the intensity of the staining. The counts were done in the fields with the more numerous stained nuclei. These were mostly located at the border of the tumor for NSCLC. All cells were counted in the fields. Cytoplasmic and/or nuclear localization of p-akt was reported as positive. Statistical Analysis Comparative nuclear expression of p-erk between the studied groups was estimated using the unpaired two-tailed t-test. Data are shown as box plots representing median and lower and higher values, as well as first and third quartiles. Analysis was performed using the software GraphPrism version 3.00 for Windows (GraphPad Software; San Diego, CA). A p value #0.05 was considered statistically significant. Results Figure 1 shows that % of nuclei were stained in MM as compared with % in poorly differentiated NSCLC (p,0.05), % in welldifferentiated NSCLC (p,0.0001), and % in non-neoplastic tissue sections (p,0.0001). Furthermore,

3 p-erk Activation in Mesothelioma and Lung Carcinoma 857 expression of p-erk was significantly increased in poorly differentiated NSCLC as compared with welldifferentiated NSCLC (p,0.01) and normal lung tissue (p,0.01). Conversely, the percentage of nuclei stained in well-differentiated NSCLC was not statistically different from control lung tissue sections. The expression of p-erk in two types of NSCLC (namely, adenocarcinoma and squamous cell carcinoma) is detailed in Figure 2. Poorly differentiated tumors showed a higher percentage of nuclei stained with p- ERK than well-differentiated tumors in both types (p,0.05), with a more scattered distribution of p-erk expression in the former. Variation in the levels of activation was observed in three cases of adenocarcinoma. One poorly differentiated case showed 4% staining, whereas two others with a well-differentiated grade resulted in positive staining values of 12% and 16%, respectively. This heterogeneity could reflect transition changes involving the overexpression of other elements in the transduction cascades during carcinogenesis. Immunohistochemical Localization of p-erk in MM and NSCLC The pattern of MM staining, including epithelioid, sarcomatous, and biphasic phenotypes, showed intense, homogeneous staining both in the cytoplasm and in the nucleus, reflecting high levels of p-erk activation in these cells (Figures 3E and 3F). The qualitative analysis of the NSCLC sections revealed a very heterogeneous pattern of MAP kinase staining in both the cytoplasm and nucleus of the primary tumor, varying from weak, Figure 2 Expression of activated p-erk nuclear staining (%) in welland poorly differentiated non-small-cell lung carcinoma. (A) Adenocarcinoma. (B) Squamous cell carcinoma. *p to moderate, to intense (Figures 3G 3J). Frequently, positive clusters of cells localized at the periphery of tumors in the region of the edge of growing zones, whereas the centers of the tumor region were completely negative (Figure 3G). However, in all NSCLC we occasionally found a few positive staining cells in the central regions of the tumor. This cellular staining was extended to both groups of NSCLC (data not shown). Four negative cases among the NSCLC were detected. Non-tumoral cells around the tumor stained more frequently than others located more distantly, possibly as a result of paracrine stimulus (Figure 3D). In the non-neoplastic sections, p-erk detection located in rare pneumocytes, fibroblasts, and endothelial cells (Figure 3B). The total ERK antibody showed a uniform cytoplasmic staining distribution. Nuclear positivity with this antibody distributed heterogeneously in relation to tissue distribution (Figure 3C). After incubation of p-erk with the blocking peptide, no immunostain was observed (Figure 4B). Immunohistochemical Localization of p-akt in MM and NSCLC p-akt colored all mesotheliomas. The staining pattern was either nuclear or cytoplasmic (Figure 4C). For NSCLC, the four squamous cell carcinomas were tested and stained in the nucleus and/or in the cytoplasm. For the five adenocarcinomas tested, three were negative and two stained in the nucleus and/or in the cytoplasm. After incubation of p-akt with the blocking peptide, no immunostaining was observed (Figure 4D). Figure 1 Expression of activated p-erk nuclear staining (%) in malignant mesothelioma (MM), poorly differentiated non-small-cell lung carcinoma (NSCLCpoor), well-differentiated non-small-cell lung carcinoma (NSCLCwell), and non-tumoral lung tissue (control). Box plots represent median, first quartile (Q 1 ), third quartile (Q 3 ), lower value, and higher value. Statistical significance between different bars: a vs. b,,0.05; a vs. d,,0.0001; b vs. c and b vs. d,,0.01; c vs. d, non-significant. Discussion The results presented in this study demonstrate that the nuclear quantification of p-erk is significantly increased in MM and in poorly differentiated NSCLC in comparison to control lung. In addition, we show that p-erk is significantly increased in poorly differentiated NSCLC as opposed to well-differentiated NSCLC. p-akt stain was observed in all MM and some NSCLC.

4 858 de Melo, Gerbase, Curran, Pache

5 p-erk Activation in Mesothelioma and Lung Carcinoma 859 Figure 4 Immunohistochemistry of activated p-erk in MM (A) and after incubation with the blocking peptide (B). Immunohistochemistry of activated p-akt in MM (C) and after incubation with the blocking peptide (D). Note the absence of staining in the negative controls. The use of highly specific antibodies that recognize activated signaling molecules within the cellular context allows the analysis of potential relationships between intracellular phosphorylation mechanisms and tumorigenesis. With this approach, one examines in situ the evidence for aberrant signals, as manifested by a change in the levels of activated proteins and/or their cellular localization. Furthermore, we can observe perturbations in a particular intracellular pathway that may lead to the promotion of abnormal cell proliferation. Few studies investigated the role of ERK in MM and NSCLC. Ramos-Nino and coworkers (2002) reported that inhibition of ERK activation abrogated mesothelioma cell growth in soft agar and restored contact inhibition. Mukohara et al. (2003) found that, in NSCLC, the level of EGF-r expression was associated with the expression of p-erk, but staining for p-erk was not significantly correlated to any clinicopathological factor. In our study, p-erk was significantly increased for poorly differentiated NSCLC. However, p-erk expression was significantly decreased in the remaining welldifferentiated cases in relation to the totality of NSCLC cases. Earlier work (Mukohara et al. 2003) employed a quantification system based on the intensity of the nuclear staining, an approach somewhat different from that adopted in this study. In a recent report, Vicent and collaborators (2004) observed a strong correlation between nuclear and cy- Figure 3 Immunohistochemistry of activated p-erk in human tissues. (A) Negative control. (B) Normal lung tissues and bronchial epithelium: negative, rare positive cells (arrows). (C) Tumor tissue stained for total protein phosphorylation-independent antibody showing a uniform distribution pattern. (D) Poorly differentiated squamous cell carcinoma. Normal cells around the tumor are activated in a paracrine fashion (arrows). (E) Mesothelioma, epithelioid cell type. (F) Mesothelioma, sarcomatous cell type. (G) Poorly differentiated adenocarcinoma showing immunostaining localized in the periphery of the tumor. (H) Well-differentiated adenocarcinoma. (I) Poorly differentiated squamous cell carcinoma. (J) Well-differentiated squamous cell carcinoma. Sections were counterstained with hematoxylin. Original magnification: A C,E J 53400; D

6 860 de Melo, Gerbase, Curran, Pache toplasmic p-erk staining and advanced stages of NSCLC. Our results add to this report. However, methodological differences limit the comparison between studies. The quantification criterion used in their earlier report was different from that employed in our study, in that a cutoff of 15% was chosen for considering a positive p-erk. Using this approach, all of our well-differentiated carcinoma cases would have been negative for p-erk with the exception of one adenocarcinoma. Indeed, this could explain the absence of correlation between the nuclear p-erk expression and the degree of tumor differentiation as reported by authors in the previous study. On the other hand, whereas moderately differentiated carcinoma cases were included in the well-differentiated group by Vicent and coworkers, in our study they were placed in the poorly differentiated NSCLC group. Our quantitative data show a statistically significant increase in the nuclear expression of p-erk in MM and in poorly differentiated NSCLC compared with controls. This corroborates previous results by Albanell et al. (2001) who reported similar percentages of cells stained for p-erk expression in head and neck squamous cell carcinoma. This microscopic approach allows a spatial localization of p-erk in the tumor tissue as well as in the subcellular compartments. High levels of nuclear p-erk were equally found at the frontal growth area and at the peripheral region of the tumor in both categories of NSCLC. Others studies have shown the presence of p-erk preferentially in the invading front of the tumor (Albanell et al. 2001). The fact that activated p-erk was also detected in normal cells around tumor regions may be explained by the induction of growth factors such as TGF-a and PDGF, which stimulate the proliferation of the tumor in an autocrine fashion and also the surrounding normal cells in a paracrine fashion (Hoshino et al. 1999). Moreover, our study indicates that poorly differentiated NSCLC showed a significantly increased nuclear expression of p-erk in comparison to well-differentiated NSCLC. In the two categories of NSCLC used in this study, namely, squamous cell carcinoma and adenocarcinoma, the quantitative analysis of the nuclear localization of p-erk revealed a marked increase in poorly differentiated grades. In addition, MM showed a significantly increased nuclear expression of p-erk in comparison to poorly differentiated NSCLC. These findings suggest that high levels of MAPK activation occur in MM and in poorly differentiated NSCLC. Additional signaling pathways are also activated in MM and NSCLC as shown by the p-akt immunostains. In conclusion, data presented in this study suggest that phosphorylation of ERK may constitute a relevant process in regulating cell proliferation in MM and in poorly differentiated NSCLC. As a consequence, blocking the MAPK pathway by specific inhibition of the EGF-r could have a determinant role in lung cancer treatment (Averbuch 2002; Lonardo et al. 2002). Jänne et al. (2002) reported that in MM cell lines small moecular inhibitors significantly perturbed signaling that depends on activation of EGF-r, including phosphorylation of ERK-1 and -2. Such an approach may have therapeutic applications to the clinical setting. However, to what extent it represents a real target for future drug therapy remains to be demonstrated. Acknowledgments The authors thank Professor Anastase Spiliopoulos for his support and Professor Brooke Mossman for insightful discussion of the results. The authors acknowledge the helpful contributions of the Immunopathology Laboratory staff, as well as the editorial support of Alberte Polichouk, Jean- Claude Rumbeli, and Etienne Denkinger. Literature Cited Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, et al. (2001) Activated extracellular signalregulated kinases: association with epidermal growth factor receptor/transforming growth factor expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61: Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, et al. (2005) Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24: Averbuch SD (2002) Lung cancer prevention: retinoids and the epidermal growth factor receptor a phoenix rising? Clin Cancer Res 8:1 3 Cacciotti P, Strizzi L, Vianale G, Iaccheri L, Libener R, Porta C, Tognon M, et al. (2002) The presence of Simian-virus 40 sequences in mesothelioma and mesothelial cell is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol 26: Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: Hilger RA, Scheulen ME, Strumberg D (2002) The Ras-Raf-MEK- ERK pathway in the treatment of cancer. Onkologie 25: Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, et al. (1999) Constitutive activation of the 41/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: Ishikawa Y, Kitamura M (1999) Dual potential of extracellular signal-regulated kinase for the control of cell survival. Biochem Biophys Res Commun 264: Jänne PM, Taffaro ML, Salgia R, Johnson BE (2002) Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62: Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, Sekula D, Knauth EA, et al. (2002) Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 8:54 60 Mandell JW, Hussaini IM, Lecevic M, Weber MJ, Vandenberg SR (1998) In-situ visualization of intratumor growth factor signaling. Am J Pathol 153: Mossman BT, Bignon J, Corn M, Seaton A, Gee JBL (1990) Asbestos: scientific developments and implications for public policy. Science 247: Mossman BT, Gruenert DC (2002) SV 40, growth factors, and mesothelioma. Another piece of the puzzle. Am J Respir Cell Mol Biol 26:

7 p-erk Activation in Mesothelioma and Lung Carcinoma 861 Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N, Kanazawa H, Hirata K, et al. (2003) Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 41: Platanias LC (2003) Map kinase signaling pathways and hematologic malignancies. Blood 101: Ramos-Nino ME, Timblin CR, Mossman BT (2002) Mesothelial cell transformation requires increased AP-1 binding activity and ERKdependant Fra-1 expression. Cancer Res 62: Reddy KB, Nabha SM, Atanaskova N (2003) Role of MAP kinase in tumor progression and invasion. Cancer Metatasis Rev 22: Rizzo P, Bocchetta M, Powers A, Foddis R, Stekala E, Pass H, Carbone M (2001) SV 40 and the pathogenesis of mesothelioma. Semin Cancer Biol 11:63 71 Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (2004) Pathology & Genetics Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of Tumours, IARC Press, Lyon Viallet J, Sausville EA (1996) Involvement of signal transduction pathways in lung cancer biology. J Cell Biochem 24(suppl): Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia- Corchon C, Quero C, et al. (2004) ERK1/2 is activated in nonsmall-cell lung cancer and associated with advanced tumours. Br J Cancer 90: Zanella CL, Posada J, Tritton TR, Mossman BT (1996) Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 56:

The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin

The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,

More information

Diagnostic Challenge. Department of Pathology,

Diagnostic Challenge. Department of Pathology, Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital

More information

A 70-year old Man with Pleural Effusion

A 70-year old Man with Pleural Effusion Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

P4 Distribution of Cetuximab in Models of Human Lung Cancer

P4 Distribution of Cetuximab in Models of Human Lung Cancer Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, University of Tübingen, Robert Bosch Foundation Stuttgart, Germany FORSYS Partner Project Predictive Cancer Therapy Project Meeting 14.10.09

More information

Update on Mesothelioma

Update on Mesothelioma November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical

More information

M. Ugolini 1,2, G. Babini 1,2, G. Baiocco 1,2, D. Cappelletti 1,2, L. Mariotti 1,2, J. Morini 1,2,3 and A. Ottolenghi 1,2

M. Ugolini 1,2, G. Babini 1,2, G. Baiocco 1,2, D. Cappelletti 1,2, L. Mariotti 1,2, J. Morini 1,2,3 and A. Ottolenghi 1,2 M. Ugolini 1,2, G. Babini 1,2, G. Baiocco 1,2, D. Cappelletti 1,2, L. Mariotti 1,2, J. Morini 1,2,3 and A. Ottolenghi 1,2 1 Department of Physics, University of Pavia, Pavia, Italy 2 Istituto Nazionale

More information

Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies. Biochemistry Journal. August 1, 2007 405, pp.

Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies. Biochemistry Journal. August 1, 2007 405, pp. Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies 1 Biochemistry Journal August 1, 2007 405, pp. 559 568 Joseph Friedman, Sarah Kraus, Yirmi Hauptman, Yoni Schiff

More information

YOUR LUNG CANCER PATHOLOGY REPORT

YOUR LUNG CANCER PATHOLOGY REPORT UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7

More information

HER2 Testing in Breast Cancer

HER2 Testing in Breast Cancer HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor

More information

The following information is only meant for people who have been diagnosed with advanced non-small cell

The following information is only meant for people who have been diagnosed with advanced non-small cell Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC

More information

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Outline. Workup for metastatic breast cancer. Metastatic breast cancer Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30

More information

Lung Cancer Research: From Prevention to Cure!

Lung Cancer Research: From Prevention to Cure! Lung Cancer Research: From Prevention to Cure! Ravi Salgia, M.D, Ph.D Associate Professor of Medicine Director, Thoracic Oncology Research Program Department of Medicine Section of Hematology/Oncology

More information

Outline. 1. Experiment. 2. Sample analysis and storage. 3. Image analysis and presenting data. 4. Probemaker

Outline. 1. Experiment. 2. Sample analysis and storage. 3. Image analysis and presenting data. 4. Probemaker Tips and tricks Note: this is just an informative document with general recommendations. Please contact support@olink.com should you have any queries. Document last reviewed 2011-11-17 Outline 1. Experiment

More information

The Diagnosis of Cancer in the Pathology Laboratory

The Diagnosis of Cancer in the Pathology Laboratory The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

A disease of populations of cells that live, divide, invade and spread without regard to normal limits

A disease of populations of cells that live, divide, invade and spread without regard to normal limits 1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

Future Oncology: Technology, Products, Market and Service Opportunities

Future Oncology: Technology, Products, Market and Service Opportunities Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter

More information

FULLY AUTOMATED PARALLEL DUAL STAINING DETECTION SYSTEM. ChromoPlex 1 Dual Detection for BOND

FULLY AUTOMATED PARALLEL DUAL STAINING DETECTION SYSTEM. ChromoPlex 1 Dual Detection for BOND ChromoPlex 1 Dual Detection for BOND FULLY AUTOMATED PARALLEL DUAL STAINING DETECTION SYSTEM View multiple antibodies on a single slide to deliver a comprehensive clinical result. 1 MULTIPLY YOUR CAPABILITIES

More information

Department of BioScience Technology Chung Yuan Christian University 2015/08/13

Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Principles of Immunohistochemistry Queen s Laboratory For Molecular Pathology

Principles of Immunohistochemistry Queen s Laboratory For Molecular Pathology Principles of Immunohistochemistry Queen s Laboratory For Molecular Pathology Table of Contents POLYCLONAL VERSUS MONOCLONAL ANTIBODIES...PAGE 3 DIRECT & INDIRECT ASSAYS.PAGE 4 LABELS..PAGE 5 DETECTION...PAGE

More information

White paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-braf V600E (VE1) Antibody: A Comparison with Sanger

White paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-braf V600E (VE1) Antibody: A Comparison with Sanger White paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-braf V600E (VE1) Antibody: A Comparison with Sanger Sequencing 2 Evaluation of BRAF (V600E) Mutation by Immunohistochemical

More information

Practical Effusion Cytology

Practical Effusion Cytology Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.

More information

Digital Pathology Image Analysis with Definiens

Digital Pathology Image Analysis with Definiens Understanding Images DEEPER INSIGHTS FASTER RESULTS BETTER DECISIONS Digital Pathology Image Analysis with Definiens 2,05 0,012 coexpression 10000 circularity infiltration biomarker intensity 48 mitotic

More information

20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.

20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC. Utility of WT-1, p63, MOC31, Mesothelin, and Cytokeratin (K903 and CK5/6) Immunostains in Differentiating Adenocarcinoma, Squamous Cell Carcinoma, and Malignant Mesothelioma in Effusions Robert T. Pu,

More information

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy

More information

Targeted Therapies in Lung Cancer

Targeted Therapies in Lung Cancer Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why

More information

Hypoxyprobe -1 Plus Kit Kit contents:

Hypoxyprobe -1 Plus Kit Kit contents: Updated 2015 1 PRODUCT INSERT Hypoxyprobe, Inc 121 Middlesex Turnpike Burlington, MA 01803 USA www.hypoxyprobe.com Hypoxyprobe -1 Plus Kit Kit contents: Solid pimonidazole HCl (Hypoxyprobe -1) FITC conjugated

More information

Analysis of the Tumour Microenvironment with Computer Vision

Analysis of the Tumour Microenvironment with Computer Vision Analysis of the Tumour Microenvironment with Computer Vision Johan Lundin, MD, PhD Research Director Institute for Molecular Medicine Finland FIMM University of Helsinki and Guest Professor, Karolinska

More information

Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.

Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion. Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case

More information

Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium

Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%

More information

PATHOLOGY. HercepTestTM. Product Information

PATHOLOGY. HercepTestTM. Product Information PATHOLOGY HercepTestTM Product Information CLINICAL TRIALS HercepTest The First and Foremost Dako s pharmdx HercepTest was the first FDA-approved assay developed exclusively to aid physicians in identifying

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer

More information

Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1)

Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1) Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1) Verónica Cánovas, PhD Student Laboratory of Cell Signalling and Cancer Progression, Dra. Rosanna Paciucci

More information

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative

More information

Diagnosis of Mesothelioma Pitfalls and Practical Information

Diagnosis of Mesothelioma Pitfalls and Practical Information Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com

More information

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied

More information

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,

More information

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods

More information

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function: Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

Immunohistochemistry. Services & Products. Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany

Immunohistochemistry. Services & Products. Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany Services & Products Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany Phone Europe: +49-40-41 33 83-0 Fax Europe: +49-40-41 33 83-14 Phone USA: +1-301-588-4650 info@indivumed.com www.indivumed.com

More information

Notch 1 -dependent regulation of cell fate in colorectal cancer

Notch 1 -dependent regulation of cell fate in colorectal cancer Notch 1 -dependent regulation of cell fate in colorectal cancer Referees: PD Dr. Tobias Dick Prof. Dr. Wilfried Roth http://d-nb.info/1057851272 CONTENTS Summary 1 Zusammenfassung 2 1 INTRODUCTION 3 1.1

More information

Lesson 3 Reading Material: Oncogenes and Tumor Suppressor Genes

Lesson 3 Reading Material: Oncogenes and Tumor Suppressor Genes Lesson 3 Reading Material: Oncogenes and Tumor Suppressor Genes Becoming a cancer cell isn t easy One of the fundamental molecular characteristics of cancer is that it does not develop all at once, but

More information

Lung cancer is not just one disease. There are two main types of lung cancer:

Lung cancer is not just one disease. There are two main types of lung cancer: 1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available

More information

Product Datasheet and Instructions for Use

Product Datasheet and Instructions for Use Product Code: MP-092-CR01 (0.1ml concentrate) MP-092-CR05 (0.5ml concentrate) MP-092-CR1 (1ml concentrate) MP-092-PR6 (6ml RTU) Product Description: Calretinin Concentrated and Prediluted Polyclonal Antibody

More information

Protein Analysis. -Detection and quantification. Toby M Holmes

Protein Analysis. -Detection and quantification. Toby M Holmes Protein Analysis -Detection and quantification Toby M Holmes Clinical Research Unit UCD school of Medicine and Medical Sciences Mater Misericordiae University Hospital Dublin Protein structure General

More information

The develpemental origin of mesothelium

The develpemental origin of mesothelium Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal

More information

Bottlenecks in Clinical Source Material Acquisition. Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA amathew@biolifesolutions.

Bottlenecks in Clinical Source Material Acquisition. Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA amathew@biolifesolutions. Bottlenecks in Clinical Source Material Acquisition Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA amathew@biolifesolutions.com Biopreservation What s the issue? Biopreservation considerations

More information

ACC (#3676), AMPK α1/2 (#2532), AMPKβ1/2 (#4150), Phospho-4E-BP1 Thr37/46. Cell Signaling. Ki-67 Clon MIB-1 from Dako. AntiBrdU (B2531), α Tubulin

ACC (#3676), AMPK α1/2 (#2532), AMPKβ1/2 (#4150), Phospho-4E-BP1 Thr37/46. Cell Signaling. Ki-67 Clon MIB-1 from Dako. AntiBrdU (B2531), α Tubulin Supplemental materials and methods Antibodies and reagents ACC (#3676), AMPK α1/2 (#2532), AMPKβ1/2 (#4150), Phospho-4E-BP1 Thr37/46 (#9459), pakt Ser473 (#4051), pampk Thr172 (#2535), pacc Ser79 (#3661),

More information

Humoral response to therapeutic low-intensity pulsed ultrasound (LIPUS) treatment of rat maxillary socket after the removal of a molar tooth

Humoral response to therapeutic low-intensity pulsed ultrasound (LIPUS) treatment of rat maxillary socket after the removal of a molar tooth Humoral response to therapeutic low-intensity pulsed ultrasound (LIPUS) treatment of rat maxillary socket after the removal of a molar tooth Kouki Hidaka *1, Chihiro Miyamoto *2, Satoko Wada-Takahashi

More information

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,

More information

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology Lung Carcinomas New 2015 WHO Classification Spasenija Savic Pathology ***EXPECTED SPRING 2015*** This authoritative, concise reference book provides an international standard for oncologists and pathologists

More information

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred

More information

ab176915 StayBlue/AP Plus Stain Kit Instructions for Use An immunohistochemical chromogen substrate for staining tissue sections

ab176915 StayBlue/AP Plus Stain Kit Instructions for Use An immunohistochemical chromogen substrate for staining tissue sections ab176915 StayBlue/AP Plus Stain Kit Instructions for Use An immunohistochemical chromogen substrate for staining tissue sections This product is for research use only and is not intended for diagnostic

More information

Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas

Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies

More information

Male. Female. Death rates from lung cancer in USA

Male. Female. Death rates from lung cancer in USA Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita

More information

Materials and Methods Specimens

Materials and Methods Specimens The Expression Pattern of b-catenin in Mesothelial Proliferative Lesions and Its Diagnostic Utilities Yiran Dai, M.D., 1 * Carlos W.M. Bedrossian, M.D., FIAC, 2 and Claire W. Michael, M.D. 1 b-catenin

More information

OBJECTIVES By the end of this segment, the community participant will be able to:

OBJECTIVES By the end of this segment, the community participant will be able to: Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

More information

New Insights into Merkel Cell Carcinoma

New Insights into Merkel Cell Carcinoma New Insights into Merkel Cell Carcinoma Bruce R. Smoller, MD Professor and Chair, Department of Pathology Professor, Department of Dermatology University of Arkansas for Medical Sciences Merkel cell carcinoma

More information

Product Datasheet and Instructions for Use

Product Datasheet and Instructions for Use Product Code: MP-378-CMK01 (0.1ml conc) MP-378-CMK05 (0.5ml conc) MP-378-PM6 (6ml RTU) Product Description: CD141 (Thrombomodulin) Concentrated and Prediluted Monoclonal Antibody Control Number: 901-378-071709

More information

The Journal of Experimental Medicine

The Journal of Experimental Medicine [ID]FIGS1[/ID] [ID]FIGS2[/ID] [ID]FIGS3[/ID] [ID]FIGS4[/ID] [ID]FIGS5[/ID] [ID]FIGS6[/ID] [ID]TBLS1[/ID] [ID]TBLS2[/ID] SUPPLEMENTAL MATERIAL Wolf et al., http://www.jem.org/cgi/content/full/jem.20101470/dc1

More information

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent

More information

Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma

Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma g Tumor Res. Basel, Karger, 2014, vol 41, pp 98 112 (DOI: 10.1159/000355906) Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma Marc Pracht Dominik Berthold Medical Oncology Unit,

More information

March 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,

March 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith, Dr. Daniel Duvall, Medical Officer Center for Medicare, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dr. Edith Hambrick,

More information

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

HER2 Status: What is the Difference Between Breast and Gastric Cancer? Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma

Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Author's response to reviews Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Authors: Tanner L Bartholow (bartholow.tanner@medstudent.pitt.edu) Uma R Chandran (chandranur@msx.upmc.edu)

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

Understanding your pathology report

Understanding your pathology report Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

Immunohistochemical Expression of Osteopontin in Epithelioid Mesotheliomas and Reactive Mesothelial Proliferations

Immunohistochemical Expression of Osteopontin in Epithelioid Mesotheliomas and Reactive Mesothelial Proliferations natomic Pathology / OSTEOPONTIN IN MESOTHELIL PROLIFERTIONS Immunohistochemical Expression of Osteopontin in Epithelioid Mesotheliomas and Reactive Mesothelial Proliferations Dean-Yar Tigrani, MD, and

More information

Recommendations for the Reporting of Pleural Mesothelioma

Recommendations for the Reporting of Pleural Mesothelioma Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reports

More information

The EGFR mutation and precision therapy for lung cancer

The EGFR mutation and precision therapy for lung cancer for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists

More information

Preparation of a phosphotyrosinylated protein standard for 2D gel western blotting

Preparation of a phosphotyrosinylated protein standard for 2D gel western blotting Preparation of a phosphotyrosinylated protein standard for 2D gel western blotting Nancy Kendrick, Matt Hoelter, Andrew Koll, and Jon Johansen Kendrick Labs, Inc, Madison, WI www.kendricklabs.com Introduction

More information

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But

More information

Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient

Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that

More information

CHAPTER 2: UNDERSTANDING CANCER

CHAPTER 2: UNDERSTANDING CANCER CHAPTER 2: UNDERSTANDING CANCER INTRODUCTION We are witnessing an era of great discovery in the field of cancer research. New insights into the causes and development of cancer are emerging. These discoveries

More information

TFE3 (MRQ-37) Rabbit Monoclonal Antibody PRODUCT AVAILABILITY SYMBOL DEFINITIONS INTENDED USE PRINCIPLES AND PROCEDURES SUMMARY AND EXPLANATION

TFE3 (MRQ-37) Rabbit Monoclonal Antibody PRODUCT AVAILABILITY SYMBOL DEFINITIONS INTENDED USE PRINCIPLES AND PROCEDURES SUMMARY AND EXPLANATION Rev. 0.0 TFE3 (MRQ-37) Rabbit Monoclonal Antibody PRODUCT AVAILABILITY Cat. No. Description 354R-14 0.1 ml, concentrate 354R-15 0.5 ml, concentrate 354R-16 1.0 ml, concentrate 354R-17 1.0 ml, predilute

More information

Pathologist s Discussion of Plaintiffs Latest Theories

Pathologist s Discussion of Plaintiffs Latest Theories Pathologist s Discussion of Plaintiffs Latest Theories Mary Beth Beasley, MD Mt. Sinai Medical Center Annenberg Building 15th Floor Room 50 1468 Madison Avenue New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com

More information

Cytopathology Case Presentation #8

Cytopathology Case Presentation #8 Cytopathology Case Presentation #8 Emily E. Volk, MD William Beaumont Hospital, Troy, MI Jonathan H. Hughes, MD Laboratory Medicine Consultants, Las Vegas, Nevada Clinical History 44 year old woman presents

More information

Cancer patients waiting for potentially live-saving treatments in UK

Cancer patients waiting for potentially live-saving treatments in UK Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.

More information

Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic

Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic Pulling the Plug on Cancer Cell Communication Stephen M. Ansell, MD, PhD Mayo Clinic Why do Waldenstrom s cells need to communicate? Waldenstrom s cells need activating signals to stay alive. WM cells

More information

BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner

BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome Thomas Wiesner Disclosure Listed as co-inventor US patent application US 61/463,389 BAP1 mutational analysis in determining susceptibility

More information

Rare Thoracic Tumours

Rare Thoracic Tumours Rare Thoracic Tumours 1. Epithelial Tumour of Trachea 1 1.1 General Results Table 1. Epithelial Tumours of Trachea: Incidence, Trends, Survival Flemish Region 2001-2010 Both Sexes Incidence Trend EAPC

More information

Uses of Flow Cytometry

Uses of Flow Cytometry Uses of Flow Cytometry 1. Multicolour analysis... 2 2. Cell Cycle and Proliferation... 3 a. Analysis of Cellular DNA Content... 4 b. Cell Proliferation Assays... 5 3. Immunology... 6 4. Apoptosis... 7

More information

Case of the. Month October, 2012

Case of the. Month October, 2012 Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix

More information

ab183294 TripleStain IHC Kit: M&M&R on rodent tissue (DAB, DAB/Ni & AP/Red)

ab183294 TripleStain IHC Kit: M&M&R on rodent tissue (DAB, DAB/Ni & AP/Red) ab183294 TripleStain IHC Kit: M&M&R on rodent tissue (DAB, DAB/Ni & AP/Red) Instructions for Use For the detection of Rabbit and Mouse Primary antibodies on Rodent Tissue. This product is for research

More information

PNL2 MELANOCYTIC MARKER IN IMMUNOHISTOCHEMICAL EVALUATION OF PRIMARY MUCOSAL MELANOMA OF THE HEAD AND NECK

PNL2 MELANOCYTIC MARKER IN IMMUNOHISTOCHEMICAL EVALUATION OF PRIMARY MUCOSAL MELANOMA OF THE HEAD AND NECK ORIGINAL ARTICLE PNL2 MELANOCYTIC MARKER IN IMMUNOHISTOCHEMICAL EVALUATION OF PRIMARY MUCOSAL MELANOMA OF THE HEAD AND NECK Luc G. Morris, MD, 1 Yong Hannah Wen, MD, PhD, 2 Daisuke Nonaka, MD, 2 Mark D.

More information

HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download

HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP2003R1 http://hkcpath.org. Correspondence: pkhui@ha.org.hk 1of 10 07/08/2003 HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP141 Bone Marrow: Metastatic Carcinoma from

More information

HER2 Testing in Gastric and Esophageal Adenocarcinoma: Emerging Therapeutic Options and Diagnostic Challenges

HER2 Testing in Gastric and Esophageal Adenocarcinoma: Emerging Therapeutic Options and Diagnostic Challenges Technical Articles HER2 Testing in Gastric and Esophageal Adenocarcinoma: Emerging Therapeutic Options and Diagnostic Challenges Christa L. Whitney-Miller, MD David G. Hicks, MD Department of Pathology

More information

EDUCATION. HercepTest TM. Interpretation Manual Breast Cancer

EDUCATION. HercepTest TM. Interpretation Manual Breast Cancer EDUCATION HercepTest TM Interpretation Manual Breast Cancer EDUCATION HercepTest TM Table of Contents Contents 5 Introduction 6 HER2 Overview 6 HER2 Protein and HER2 Family 6 HER2 Testing IHC and FISH

More information

Interpretation Guide for VENTANA anti-her2/neu (4B5)

Interpretation Guide for VENTANA anti-her2/neu (4B5) Interpretation Guide for VENTANA anti-her2/neu (4B5) Rabbit Monoclonal Primary Antibody Staining of Breast and Gastric Carcinoma E2451_1211C_HER2_4B5_Breast_and_Gastric_Interpretation_Guide-05.indd 1 Table

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

CytoSelect 48-Well Cell Adhesion Assay (ECM Array, Colorimetric Format)

CytoSelect 48-Well Cell Adhesion Assay (ECM Array, Colorimetric Format) Product Manual CytoSelect 48-Well Cell Adhesion Assay (ECM Array, Colorimetric Format) Catalog Number CBA-070 CBA-070-5 48 assays 5 x 48 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures

More information

Uses and Abuses of Pathology in Asbestos-exposed Populations

Uses and Abuses of Pathology in Asbestos-exposed Populations Uses and Abuses of Pathology in Asbestos-exposed Populations Jerrold L. Abraham, MD Department of Pathology State University of New York Upstate Medical University Syracuse, NY, 13210 USA The term: Asbestosis,

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information